APVO
$4.63
Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States.
Intraday
Recent News
Sector Update: Health Care Stocks Edge Higher Late Afternoon
Health care stocks were edging up late Friday afternoon with the NYSE Health Care Index and the Stat
Aptevo Therapeutics (APVO) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Aptevo Therapeutics (APVO) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Wall Street Set to Open Higher Thursday; Jobless Claims Fall as Manufacturing Index Rebounds
US stocks look set to open higher Thursday following a lower-than-expected jobless claims report and
Aptevo Meets Nasdaq $2.5M Equity Requirement
Aptevo Therapeutics Inc. (NASDAQ:APVO) is among the best get rich quick stocks to buy now. As per the announcement last Tuesday, Aptevo Therapeutics Inc. (NASDAQ:APVO) has regained compliance with the Nasdaq Listing Rule 5550(b)(1), which requires listed companies to sustain at least $2.5 million in stockholders’ equity. The company received a green signal from the […]
Aptevo announces addition of preclinical candidate APVO455 to portfolio
Aptevo Therapeutics (APVO) announced the addition of preclinical candidate APVO455 to its growing portfolio of CD3-directed candidates built on the CRIS-7 derived CD3 binding domain-an approach demonstrating compelling potential across both hematologic and solid tumors. With this announcement, Aptevo now has a suite of three CD3-engaging molecules in development. All three share the same CRIS-7 derived binding domain with a low cytokine release profile. In addition, APVO455 and APVO442 contain C